MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Aktien・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

544.84 2.82

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

534.3

Max

546.33

Schlüsselkennzahlen
By Trading Economics
Einkommen	56M -59M
Verkäufe	34M 321M
Gewinnspanne	-18.243
Angestellte	915
EBITDA	56M -50M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+28.89% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	30. Apr. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1B 12B
Vorheriger Eröffnungskurs	542.02
Vorheriger Schlusskurs	544.84

Nachrichtenstimmung

By Acuity

96%

4 / 349 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

263.2 / 277.1 Unterstützung & Widerstand

Madrigal Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Apr. 2026, 04:27 UTC

Wichtige Nachrichtenereignisse

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3. Apr. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2026, 18:30 UTC

Wichtige Nachrichtenereignisse

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3. Apr. 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3. Apr. 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3. Apr. 2026, 17:44 UTC

Akquisitionen, Fusionen, Übernahmen

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3. Apr. 2026, 16:50 UTC

Wichtige Nachrichtenereignisse

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3. Apr. 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2026, 16:12 UTC

Ergebnisse

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3. Apr. 2026, 15:56 UTC

Market Talk

Wichtige Nachrichtenereignisse

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3. Apr. 2026, 15:56 UTC

Market Talk

Wichtige Nachrichtenereignisse

Global Equities Roundup: Market Talk

3. Apr. 2026, 15:56 UTC

Market Talk

Wichtige Nachrichtenereignisse

Global Forex and Fixed Income Roundup: Market Talk

3. Apr. 2026, 15:20 UTC

Wichtige Nachrichtenereignisse

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3. Apr. 2026, 15:08 UTC

Akquisitionen, Fusionen, Übernahmen

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3. Apr. 2026, 14:11 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3. Apr. 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3. Apr. 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Apr. 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3. Apr. 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3. Apr. 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3. Apr. 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Apr. 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3. Apr. 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Apr. 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3. Apr. 2026, 04:01 UTC

Market Talk

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3. Apr. 2026, 02:01 UTC

Market Talk

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3. Apr. 2026, 01:59 UTC

Market Talk

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3. Apr. 2026, 01:44 UTC

Market Talk

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3. Apr. 2026, 01:22 UTC

Market Talk

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Peer-Vergleich

Kursveränderung

Madrigal Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

28.89% Vorteil

12-Monats-Prognose

Durchschnitt 704.88 USD 28.89%

Hoch 964 USD

Tief 529 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Madrigal Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Madrigal Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

263.2 / 277.1Unterstützung & Widerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Stimmung

By Acuity

4 / 349 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.